Imfinzi + Imjudo HCC: HIMALAYA Survival Data

Key Takeaways

• FDA approved tremelimumab (Imjudo) with durvalumab (Imfinzi) for unresectable HCC on October 21, 2022 based on HIMALAYA (NCT03298451).
• STRIDE uses tremelimumab 300 mg once plus durvalumab 1500 mg, then durvalumab every 4 weeks (weight-based alternatives for patients under 30 kg).
• Median OS was 16.4 months with the combination versus 13.8 months with sorafenib (stratified HR 0.78; 95% CI 0.66–0.92; P=0.0035).
• DailyMed labeling lists common adverse reactions (20% or higher) including rash, fatigue, diarrhea, pruritus, musculoskeletal pain, and abdominal pain.

What did FDA require from HIMALAYA for the Imfinzi–Imjudo HCC approval?

An FDA approval summary in Clinical Cancer Research states that on October 21, 2022, FDA approved tremelimumab in combination with durvalumab for adults with unresectable HCC after HIMALAYA met its primary overall-survival endpoint versus sorafenib.

Patients naïve to prior systemic therapy were randomized to tremelimumab plus durvalumab (n=393), durvalumab (n=389), or sorafenib (n=389). Stratified HR for OS was 0.78 (95% CI 0.66–0.92; P=0.0035), with median OS 16.4 versus 13.8 months.

Source: FDA approval summary DOI 10.1158/1078-0432.CCR-23-2124.

How is the STRIDE regimen dosed on the U.S. label?

For patients weighing 30 kg or more, recommended dosing is tremelimumab 300 mg IV once with durvalumab 1500 mg on Cycle 1 Day 1, then durvalumab 1500 mg IV every 4 weeks. For patients under 30 kg, tremelimumab 4 mg/kg once with durvalumab 20 mg/kg, then durvalumab 20 mg/kg every 4 weeks.

DailyMed prescribing information for IMJUDO confirms the unresectable HCC indication, the HIMALAYA efficacy basis, and combination use with durvalumab.

Label: DailyMed — IMJUDO (tremelimumab-actl).

What safety signals should EU and global teams monitor?

FDA’s summary lists adverse reactions in at least 20% of combination-treated patients as rash, fatigue, diarrhea, pruritus, musculoskeletal pain, and abdominal pain. Dual CTLA-4 and PD-L1 blockade requires the same immune-mediated toxicity pathways familiar from other IO combinations, including hepatitis, colitis, endocrinopathies, and pneumonitis monitoring plans.

Medical affairs should keep NCT03298451 as the anchor registry ID when comparing subsequent HCC IO regimens in advisory boards.

Trial registry: ClinicalTrials.gov NCT03298451 (HIMALAYA).

How should competitive positioning read in 2026?

HIMALAYA established a statistically significant OS benefit versus sorafenib for the STRIDE regimen. Later company communications have discussed multi-year survival tails, but label-level claims for field materials should stay tied to FDA and DailyMed language rather than marketing decks.

EU market-access teams should separate EMA SmPC text from U.S. STRIDE dosing when building cross-region slides, and should document Barcelona Clinic Liver Cancer stage and Child-Pugh A enrollment limits when payers ask about generalizability.

Who was excluded from HIMALAYA and why that matters?

FDA’s summary notes exclusion of patients with HBV/HCV coinfection, ascites requiring nonpharmacologic intervention, or main portal vein thrombosis in the pivotal design narrative used for labeling. Those exclusions matter when real-world HCC cohorts include more advanced vascular invasion or mixed viral etiologies.

Competitive intelligence comparisons that ignore enrollment filters overstate interchangeability across IO and TKI options.

What remains unproven or out of scope?

Do not extrapolate HIMALAYA OS benefit to earlier-stage resectable disease or to every etiology subgroup without citing the specific analysis. The approval is for unresectable HCC in the labeled combination; NSCLC combination uses are separate labeled indications and should not be blended into liver-cancer messaging.

For EU affiliate medical teams, the operational takeaway is documentation discipline: cite the October 21, 2022 FDA decision date, the NCT03298451 registry ID, the OS hazard ratio of 0.78 with its 95% confidence interval, and DailyMed dosing tables whenever comparing STRIDE with newer HCC immuno-oncology regimens. That keeps promotional and educational materials aligned with regulator-facing facts rather than secondary news summaries.

Related NovaPharma coverage

• HER2 biology and next-gen cancer treatment
• Orphan drugs 2026 outlook
• Merck Phase 3 pipeline gaps

Frequently Asked Questions

Primary Sources

1. CCR — FDA approval summary, tremelimumab + durvalumab HCC
2. DailyMed — IMJUDO label
3. ClinicalTrials.gov — HIMALAYA NCT03298451